

# Isabelle Borget

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5408705/publications.pdf>

Version: 2024-02-01

19  
papers

564  
citations

1051969

10  
h-index

993246

17  
g-index

19  
all docs

19  
docs citations

19  
times ranked

1029  
citing authors

#	ARTICLE	IF	CITATIONS
1	Patient Preference Between Cabazitaxel and Docetaxel for First-line Chemotherapy in Metastatic Castration-resistant Prostate Cancer: The CABADOC Trial. <i>European Urology</i> , 2022, 81, 234-240.	0.9	12
2	Global thyroid estimates in 2020. <i>Lancet Diabetes and Endocrinology</i> , 2022, 10, 235-236.	5.5	5
3	RADTHYR: an open-label, single-arm, prospective multicenter phase II trial of Radium-223 for the treatment of bone metastases from radioactive iodine refractory differentiated thyroid cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 3238-3249.	3.3	11
4	Imaging: towards a global solution to overcome the cancer pandemic. <i>Lancet Oncology</i> , 2021, 22, 430-432.	5.1	0
5	Impact of COVID-19 on healthcare organisation and cancer outcomes. <i>European Journal of Cancer</i> , 2021, 153, 123-132.	1.3	25
6	Prognosis of Malignant Pheochromocytoma and Paraganglioma (MAPP-Prono Study): A European Network for the Study of Adrenal Tumors Retrospective Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 2367-2374.	1.8	103
7	Quality of life and cost of strategies of two chemotherapy lines in metastatic colorectal cancer: results of the FFCO 2000-05 trial. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2019, 19, 601-608.	0.7	1
8	Final results from the randomized CABADOC trial: Patient preference between cabazitaxel and docetaxel for first-line chemotherapy in metastatic castrate-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 5017-5017.	0.8	2
9	Lenvatinib for the Treatment of Radioiodine-Refractory Thyroid Cancer in Real-Life Practice. <i>Thyroid</i> , 2018, 28, 72-78.	2.4	89
10	Outcome after ablation in patients with low-risk thyroid cancer (ESTIMABL1): 5-year follow-up results of a randomised, phase 3, equivalence trial. <i>Lancet Diabetes and Endocrinology</i> , 2018, 6, 618-626.	5.5	115
11	Olanzapine as antiemetic drug in oncology: a retrospective study in non-responders to standard antiemetic therapy. <i>International Journal of Clinical Pharmacy</i> , 2018, 40, 1265-1271.	1.0	5
12	Radioactive iodine ablation in low-risk thyroid cancer – Authors' reply. <i>Lancet Diabetes and Endocrinology</i> , 2018, 6, 686-687.	5.5	3
13	Circulating Tumor Cells with Aberrant <i>ALK</i> Copy Number Predict Progression-Free Survival during Crizotinib Treatment in <i>ALK</i> -Rearranged Non-Small Cell Lung Cancer Patients. <i>Cancer Research</i> , 2017, 77, 2222-2230.	0.4	64
14	The intensity of 18FDG uptake does not predict tumor growth in patients with metastatic differentiated thyroid cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 638-646.	3.3	16
15	Prognostic role of a comprehensive geriatric assessment on the management of elderly patients with advanced non-small cell lung cancer (NSCLC): a pooled analysis of two prospective phase II trials by the GFPC Group. <i>Journal of Thoracic Disease</i> , 2017, 9, 3747-3754.	0.6	12
16	The challenge of rapid diagnosis in oncology: Diagnostic accuracy and cost analysis of a large-scale one-stop breast clinic. <i>European Journal of Cancer</i> , 2016, 66, 131-137.	1.3	33
17	<i>ALK</i> -amplified circulating tumor cells as a surrogate marker for crizotinib benefit in <i>ALK</i> -rearranged non-small cell lung cancer patients.. <i>Journal of Clinical Oncology</i> , 2016, 34, 11515-11515.	0.8	0
18	Dosimetric Effects of the Interfraction Variations during Whole Breast Radiotherapy: A Prospective Study. <i>Frontiers in Oncology</i> , 2015, 5, 199.	1.3	5

#	ARTICLE	IF	CITATIONS
19	Quality of Life and Cost-Effectiveness Assessment of Radioiodine Ablation Strategies in Patients With Thyroid Cancer: Results From the Randomized Phase III ESTIMABL Trial. <i>Journal of Clinical Oncology</i> , 2015, 33, 2885-2892.	0.8	63